Target Audience
This program is intended for medical oncologists, hematology-oncology fellows, radiation oncologists and other healthcare professionals involved in the treatment of melanoma and nonmelanoma skin cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Identify factors affecting the risk of recurrence for patients with localized melanoma, and evaluate the role of approved targeted and immunotherapeutic agents as adjuvant therapy.
• Use available clinical trial evidence to safely and effectively incorporate immunotherapeutic, targeted or combination approaches into the management of newly diagnosed metastatic melanoma.
• Consider age, performance status and other biological and disease-related factors in the selection of therapy — including potential clinical trial participation — for patients with metastatic melanoma who experience disease progression on front-line immune checkpoint inhibitor-based treatment.
• Assess available efficacy and safety findings with anti-LAG-3 antibodies in combination with anti-PD-1/PD-L1 antibodies for advanced melanoma in order to optimally integrate this strategy into the treatment armamentarium.
• Use available clinical trial evidence to safely and effectively integrate immunotherapeutic approaches into the management of advanced cutaneous squamous cell carcinoma (cSCC).
• Formulate a long-term clinical plan for the management of advanced basal cell carcinoma (BCC), incorporating targeted and immunotherapeutic strategies.
• Evaluate clinical research findings with immunotherapeutic agents as neoadjuvant or adjuvant therapy for patients with cSCC or BCC to determine the current clinical utility of various approaches.
• Recall the design of ongoing clinical trials evaluating novel agents and strategies for melanoma, cSCC and BCC, and appropriately counsel patients about availability and participation.

CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY
The following faculty reported relevant financial relationships with ineligible entities:

Dr Khushalani — Advisory Committees and Consulting Agreements: Bristol Myers Squibb, Castle Biosciences Incorporated, Genzyme Corporation, Instil Bio, Iovance Biotherapeutics, Jounce Therapeutics, Merck, Nektar Therapeutics, Novartis, Regeneron Pharmaceuticals Inc; Contracted Research (All to Institution): Bristol Myers Squibb, Celgene Corporation, GSK, HUYA Bioscience International, Merck, Modulation Therapeutics, Novartis, Regeneron Pharmaceuticals Inc, Replimune; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Incyte Corporation; Stock Options/Ownership — Public Companies: Amarin Corporation, Asensus Surgical, Bellicum Pharmaceuticals Inc. Dr Luke — Consultancy with Compensation: AbbVie Inc, Agenus Inc, Alnylam, AskGene Pharma, Atomwise, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Castle Biosciences Incorporated, Codiak BioSciences, Crown, Cugene, Curadev, Day One Biopharmaceuticals, Eisai Inc, EMD Serono Inc, Endeavor BioMedicines, Flame Biosciences, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Geneos Therapeutics, Gilead Sciences Inc, Glenmark Pharmaceuticals, HotSpot Therapeutics, Ikena Oncology, Immatics, Immunocore, Incyte Corporation, Instil Bio, Inzen Therapeutics, IO Biotech, Janssen Biotech Inc, KoBioLabs, Krystal Biotech Inc, KSQ Therapeutics, LegoChem Biosciences, Lyvgen Biopharma, MacroGenics Inc, Merck, Mersana Therapeutics Inc, Nektar Therapeutics, Novartis, Partner Therapeutics, Pfizer Inc, Pioneering Medicines, PsiOxus Therapeutics, Regeneron Pharmaceuticals Inc, Replimune, Ribon Therapeutics, Roivant, Sanofi, Servier Pharmaceuticals LLC, Stingthera, STORM Therapeutics Ltd, Sumitomo Dainippon Pharma Oncology Inc, Synlogic, Synthekine, Teva Oncology; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Agenus Inc, Evaxion Biotech A/S, Immutep, Shionogi Inc; Research Support (All to Institution): AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Corvus Pharmaceuticals, Day One Biopharmaceuticals, EMD Serono Inc, F-star Therapeutics Inc, Genmab US Inc, HotSpot Therapeutics, Ikena Oncology, Immatics, Imugene, Incyte Corporation, Janux Therapeutics, KAHR, MacroGenics Inc, Merck, Moderna, Nektar Therapeutics, NextCure, Novartis, Numab Therapeutics AG, Palleon Pharmaceuticals, Pfizer Inc, Replimune, Rubius Therapeutics, Sanofi, Servier Pharmaceuticals LLC, Scholar Rock, Synlogic, Takeda Pharmaceuticals USA Inc, Tizona Therapeutics Inc, Trishula Therapeutics Inc, TScan Therapeutics, Werewolf Therapeutics, Xencor; Scientific Advisory Boards (No Stock): 7 Hills Pharma Inc, Affivant, BioCytics, Bright Peak Therapeutics, Exo Therapeutics Inc, F-star Therapeutics Inc, Inzen Therapeutics, RefleXion, Xilio Therapeutics; Scientific Advisory Boards (Stock): Actym Therapeutics, Alphamab Oncology, Arch Oncology, Duke Street Bio, Elpiscience, Kanaph Therapeutics, NeoTX, Onc.AI, OncoNano Medicine, physIQ, Pyxis Oncology, Saros Therapeutics, STipe Therapeutics, Tempest Therapeutics.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc,
R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by an educational grant from Merck.